ReviewDermatologie (Heidelberg, Germany)2025
[WHO classification of melanocytic tumours].
Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Melanocytic nevi in focus : Clinical interpretation, histopathological criteria, and practice-oriented management].Dermatologie (Heidelberg, Germany) · 2026Article
- Multivariate analysis and prediction model construction for distant metastasis of Acral Melanoma.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe update of the World Health Organisation (WHO) classification of skin tumours has led to new aspects in the classification of melanocytic tumours.
objectivesPresentation of the classification of melanocytic tumours in light of current clinical, histological and genetic data. MATERIALS AND
methodsReview of the classification of melanocytic neoplasms in the fifth edition of the WHO classification of skin tumours, taking into account current disease concepts.
resultsMalignant melanoma is characterised by stepwise tumour progression and is a heterogeneous disease. Benign and intermediate precursor lesions with characteristic driver mutations can be defined for the different melanoma subtypes. Melanocytomas represent a growing group of intermediate neoplasms which, from a genetic point of view, lie between nevi and melanomas and usually have a benign course.
conclusionWith the update of the WHO classification, genetic parameters are becoming increasingly relevant and shape the terminology. New terms such as 'melanocytoma' require a medical understanding of current disease concepts and good physician-patient communication for appropriate reporting of findings and therapy.
Indexed as
Identifiers
39873707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.